Rhythm Biosciences (ASX:RHY) share price jumps 12% on key milestone

The Rhythm Biosciences share price was on fire on Wednesday. Here's why…

| More on:
Lab worker puts hands in the air and dances around

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Rhythm Biosciences Ltd (ASX: RHY) share price was a very strong performer on Wednesday.

The predictive diagnostics company's shares ended the day 12% higher at $1.32.

This means the Rhythm Biosciences share price is now up 550% over the last 12 months.

Why did the Rhythm Biosciences share price surge higher today?

Investors were bidding the Rhythm Biosciences share price higher today following the release of a milestone announcement.

According to the release, the company has completed recruitment for its clinical trial (Study 7) for ColoSTAT.

ColoSTAT is a globally marketed, low-cost, simple blood test for the early detection of colorectal cancer aimed at mass-market screening.

The release explains that Rhythm Biosciences has now successfully recruited 815 patients across 11 Australian clinical trial sites. This was deemed to be an adequate number of patients following a detailed consultation with leading industry professionals and the company's biostatisticians and Clinical Research Organisation (CRO).

Management notes that the recruitment phase is a highly involved and resource intensive component of the clinical trial. Therefore, it feels the completion of this phase represents a significant milestone towards the final completion of the clinical trial study.

What's next?

The good news for the Rhythm Biosciences share price is that ColoSTAT could be generating revenue in the not so distant future.

The company will now commence testing the collected blood samples, finalise and lock the patient database, and other routine associated works. It will also progress the next stages in finalising the trial, before completing the final clinical study report.

If all goes to plan, the clinical trial is targeted for completion in the first half of calendar year 2022. After which, it is hoping for approval to market ColoSTAT within Australia later that year.

European trials are ongoing as well, with a filing expected to be made before the end of the year.

Management commentary

Rhythm's CEO, Glenn Gilbert, said: "With the recruitment target now met for the ColoSTAT clinical trial, the Company remains fully focused on working with our partners to progress through the remaining phases for trial completion."

"In the context of market conditions made extremely difficult by COVID-19, I am proud of the achievement by the entire Rhythm team, our trial sites, CRO, operations and laboratory partners. This milestone should not be understated, considering the recruitment phase is typically the most resource, logistically challenging and cost intensive component of completing a clinical trial," he added.

Management estimates that ColoSTAT has a $6.5 billion market opportunity across the US, European, and Australian markets.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

Silhouettes of nine people climbing a steep mountain to the top at sunset, and helping each other along the way.
Share Gainers

Here are the top 10 ASX 200 shares today

The markets took a turn for the worse again today.

Read more »

An executive in a suit smooths his hair and laughs as he looks at his laptop feeling surprised and delighted.
Share Gainers

Why APA, Aurelia Metals, Magnetic Resources, and ResMed shares are rising today

These shares are avoiding the market selloff on Tuesday.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a positive start to the week for ASX investors.

Read more »

Shot of a young businesswoman looking stressed out while working in an office.
Share Gainers

Why Johns Lyng, Qantas, St Barbara, and Super Retail shares are falling today

These shares are starting the week in the red. But why?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Share Gainers

Why ALS, Life360, Nuix, and Sovereign Metals shares are pushing higher today

These shares are having a good start to the week. But why?

Read more »

A man looking at his laptop and thinking.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a horrid end to the trading week this Friday.

Read more »

Three people jumping cheerfully in clear sunny weather.
Share Gainers

3 ASX 200 stocks rocketing higher this week even as the market dives

These three ASX 200 stocks are shrugging off the wider market sell-off this week to leap higher.

Read more »

Ecstatic man giving a fist pump in an office hallway.
Share Gainers

Why Insignia, Meteoric Resources, Qantas, and West African shares are pushing higher today

These shares are avoiding the market selloff today.

Read more »